Member Info for AquaeSulis01

Wouldn't disagree about the sweetbiotix comment but Andrew's comments which you cast doubts over were specifically to do with H2 revenue which will be quite a bit higher than H1

Toyin, H2 figures will be more it is a question of by how much. Known revenue for H2 from RNS - £130,000 India, £236,000 so ev0 US (this will include the sweetbiotix annual royalty and initial US slimbiome order) UK sales should continue to increase from h1 £142,000 and ROW H1 sales were £209,000 which is over £700K

LWHL,

Must agree with the spin comment. Lat year SOH saw fit to gloss over a total revenue figure that included the probiotix sales to inflate a poor years performance and this year has sought to remove them to improve comparison figures

Hold fast that India calculation, just reread the RNS and came across this comment "The business in India has a strong pipeline with emerging and leading players in weight management and sports nutrition and if launches go to plan, we would anticipate sales in the region of £130k this financial year." so goodness knows what the 500% increase figure refers to as it's certainly not based on last year's reported figure of £61K actual India revenue which was 2022 H2 based.

Agree H1 figures very disappointing but worth noting that " Improved sales performance in H1 2023 by Apollo Pharmacies (up 500%) in India and Nahdi Medical (up 30%) in Saudi Arabia following more active account management. These increased sales are not reflected in H1 but impact on restocking requirements in H2 2023". Apollo sales were £61K last year so 500% increase £300K H2. Other interesting thing when you go to the bottom of the report and look at the Geographical sales split, nothing for US H1 but in H1 2022 there was £15K revenue which means the end of year US figure of £100K means that the "6 figure" sweetbiotix annual royalty is in dollars.

One part of me is secretly hoping there is no news on display market orders or patent infringement claims before £33M of the second settlement payment arrives in Feb and hopefully given as a 10p dividend as I want to see how the market really reacts to the post dividend era where the share price is net 7p giving a M/C of £23M despite the company holding cash remains of £30M

Quiet here. I guess we're all waiting more more details on the Acne Study expected this week.

"Further details of the study will be disclosed by the end of Third Quarter 2023. "

Moniman, when Poolbeg land a big pharma deal resulting in negligible revenue to substantial revenue and profitability overnight, the shareprice will not just limp back to the IPO price it will I suspect multibag

No I didn't go but SOH did attend and was apparently given a very hard time by Lucien Miers who whilst not short on the share is a bear in the light of past performance

From the comments made in the EOY results post period and recent Commercial update, I predict the following:

"A further ten metric tonnes of SlimBiome, approximating to £300k was taken from stock held by distributors for our two largest partners, and not included in these accounts. Once this stock overhang is clear this should have a material impact on reportable revenue."

So £300K from Australian Partner and H&B if I am reading the aforementioned correctly

Launch of GoFigure® products in India with Apollo Hospitals & Pharmacies in September 2022 resulted in £61,000 revenue. Since then "á The launch in September 2022 of our GoFigure range of weight management products containing SlimBiome¨ in several pharmacies across India owned by Apollo Hospitals & Pharmacies. This number has doubled in 2023 with the aim of having products in more than 1000 stores by the end of 2023" So £120K not unreasonable. £100k from Nahdi based on £250K year forecast, and of course online sales have increased significantly from last year so further £200k possible there

So my forecast is £720K although costs will have rocketed too

Agree with that martinu; online accounted for just £0.B5 of the £6.5B 2022 revenue

SOH does not routinely announce RNS patents/updates, even the patent released in April this year related to the Microbiome Modulators failed to get a mention

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11622980

That said, improving the solubility of slimbiome in something like the weight loss shots is an important step forward as anyone who has bought and tried the shots from H&B can testify where some individual shot packets have already solidified prior to opening and are unusable and the usable shots quickly turn to gloop if not drunk fairly quickly.

Incidentally, the last patent update for sweetbiotix was Apr 2021 and identifies the different approach to treating Steviol based sweeteners (Firmenich partner) and Mogroside V (US Partner) so the novel structural concerns relating to freeze drying the Mogroside based sweetbiotix on scale up wont necessarily be encountered for the Steviol based sweetbiotix

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20210100272

A new extension to a n existing payent

Not for sweetbiotix unfortunately, but an agglomerated (granulated) form of slimbiome which potentially extends its shelflife but more importantly makes it easier to dissolve when added to water

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230292806

I can see that from the number of posts, still beats watching paint dry I guess

Time will prove who is right troublesome but we both seam to agree no downside risk at least

Troublesome, the point I am trying to make is that even without the anticipated contract announcement or license revenue recovery news from suspected patent infringers, the share price will rerate by the time the second instalment is paid in Feb because on fundamentals the pullback has been too severe and is unjustified.

So worst case scenario is no meaningful news before the final settlement is paid (circa £57.8M) shareholders get paid a 10p dividend per share costing circa £33M leaving the company with more cash left over from the settlement alone than the remaining M/C of the company based on the current sp (8p at circa £23M).

Wonder when Mr Market will finally wake up and realise this is a zero risk buy today and there is no need to wait for news on orders?

Must admit really couldn't care less whether the odd million will need to be raised of not in the light of the significant passive revenue that the company will likely receive from at least one but more likely two or three sources in 2024.

Worth reading these recently update patents to understand the excitement skinbiotix alone will generate

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230088050

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11759484

Not sure he said that notrex. Sticking to the facts; Wont get paid unless the share price goes up, assets worth more than the market cap so intends to raise awareness in the market.

What doe not change of course is that this is a junior mining exploration company yet to prove up a commercial find. Queensland is the latest hope so the company does need the money to try and prove this latest venture has the potential to be commercialised and with the injection of cash at least that hope is kept going but I guess this will be last chance saloon.